Emily Durlacher

Emily Durlacher

Auto-generated profile, based on publicly available information

Emily Durlacher

Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CPCloud P. Paweletz
Cloud P. Paweletz
GHGrace A. Heavey
Grace A. Heavey
YKYanan Kuang
Yanan Kuang
EDEmily Durlacher
Emily Durlacher
TKThian Kheoh
Thian Kheoh
PJPasi Antero Jänne
Pasi Antero Jänne
Purpose: Non-invasive monitoring of circulating tumor DNA (ctDNA) has the potential to be a readily available measure for early prediction of clinical response. Here, we report on early ctDNA changes of KRAS G12C in a Phase 2 trial of adagrasib in patients with advanced, KRAS G12C-mutant lung cancer. Experimental Design: We performed serial droplet digital PCR (ddPCR) and plasma NGS on 60 KRAS G12C-mutant patients with lung cancer that participated in cohort A of the KRYSTAL-1 clinical trial. We analyzed the change in ctDNA at 2 specific intervals: Between cycles 1 and 2 and at cycle 4. Changes in ctDNA were compared with clinical and radiographic response. Results: We found that, in general, a maximal response in KRAS G12C ctDNA levels could be observed during the initial approximately 3-week treatment period, well before the first scan at approximately 6 weeks. 35 patients (89.7%) exhibited a decrease in KRAS G12C cfDNA >90% and 33 patients (84.6%) achieved complete clearance by cycle 2. Patients with complete ctDNA clearance at cycle 2 showed an improved objective response rate (ORR) compared with patients with incomplete ctDNA clearance (60.6% vs. 33.3%). Furthermore, complete ctDNA clearance at cycle 4 was associated with an improved overall survival (14.7 vs. 5.4 months) and progression-free survival (HR, 0.3). Conclusions: These results support using early plasma response of KRAS G12C assessed at approximately 3 weeks to anticipate the likelihood of a favorable objective clinical response.

20 April 2026 in Nature Medicine
Verified
Journal Article
Open access
PDF file
ONOmar Nadeem
Omar Nadeem
DSDavid M. Cordas dos Santos
David M. Cordas dos Santos
SNSarah Nikiforow
Sarah Nikiforow
ABAnna Bosch-Vilaseca
Anna Bosch-Vilaseca
EOElizabeth O’DOnnell
Elizabeth O’DOnnell
IGIrene M. Ghobrial
Irene M. Ghobrial
High-risk smoldering multiple myeloma (HR-SMM) carries an increased risk of progression to multiple myeloma, making it an ideal setting to test whether chimeric antigen receptor (CAR) T cell therapy can achieve curative outcomes. Here in this phase 2 study, patients with HR-SMM received ciltacabtagene autoleucel (cilta-cel) at 0.3–0.5 × 106 or >0.5 × 106 viable CAR+ T cells per kilogram without induction or bridging therapy. Patients with >40% marrow involvement were excluded. Primary endpoints were dose-limiting toxicities (DLTs) and treatment-emergent adverse events; secondary endpoints included response and minimal residual disease (MRD) negativity. As of 11 February 2026, 20 patients had been treated. The trial met the prespecified endpoints. No DLTs occurred. Adverse events included transient cytopenias (90% grade 3/4) and cytokine release syndrome (100% grade 1/2). Non-immune effector cell-associated neurotoxicity syndrome neurologic toxicities (NINTs) occurred in seven patients, with four comprising cranial nerve palsies that completely resolved. Three patients had persistent grade 1 symptoms. At a median follow-up of 15.3 months, all patients achieved MRD negativity 10−6 by 2 months and have remained MRD negative. Sixteen patients with follow-up >6 months achieved a complete response; no progression or deaths were observed. Cilta-cel produced rapid, deep, sustained MRD-negative responses in HR-SMM without induction therapy. Toxicities were consistent with the safety profile of cilta-cel. ClinicalTrials.gov: NCT05767359.

25 November 2025
Verified
Other
Open access
CPCloud P. Paweletz
Cloud P. Paweletz
GHGrace A. Heavey
Grace A. Heavey
YKYanan Kuang
Yanan Kuang
EDEmily Durlacher
Emily Durlacher
TKThian Kheoh
Thian Kheoh
PJPasi Antero Jänne
Pasi Antero Jänne
Supplemental Figure 2: Baseline AF% vs sum of diameter (SOD) at baseline.

15 August 2023
Verified
Other
Open access
PDF file
CPCloud P. Paweletz
Cloud P. Paweletz
GHGrace A. Heavey
Grace A. Heavey
YKYanan Kuang
Yanan Kuang
EDEmily Durlacher
Emily Durlacher
TKThian Kheoh
Thian Kheoh
PJPasi Antero Jänne
Pasi Antero Jänne
Supplemental Figure 2: Baseline AF% vs sum of diameter (SOD) at baseline.


15 August 2023
Verified
Other
Open access
CPCloud P. Paweletz
Cloud P. Paweletz
GHGrace A. Heavey
Grace A. Heavey
YKYanan Kuang
Yanan Kuang
EDEmily Durlacher
Emily Durlacher
TKThian Kheoh
Thian Kheoh
PJPasi Antero Jänne
Pasi Antero Jänne
Data from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients